Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed malignancy expressing GD2, including, but not limited to: * Medulloblastoma/primitive neuroectodermal tumor of the CNS * Malignant glioma * Neuroblastoma * Retinoblastoma * Ependymoma * Sarcoma * Melanoma * Small cell lung carcinoma * Other tumor types must have GD2 expression confirmed by immunohistochemical staining * Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional therapy or for which no conventional therapy exists * Prior measurable human anti-mouse monoclonal antibody titer allowed PATIENT CHARACTERISTICS: Age: * 3 and over Performance status: * Not specified Life expectancy: * At least 2 months Hematopoietic: * Absolute neutrophil count greater than 1,000/mm\^3 * Platelet count greater than 50,000/mm\^3 Hepatic: * Bilirubin less than 3 mg/dL Renal: * Creatinine less than 2 mg/dL * Blood urea nitrogen less than 30 mg/dL Other: * May have active malignancy outside the central nervous system * No obstructive hydrocephalus * No CNS grade 3 or 4 toxicity as a consequence of prior treatments * No life threatening infection PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior monoclonal antibody treatment allowed Chemotherapy: * Prior chemotherapy allowed * Must have recovered from all hematopoietic and neurologic side effects of prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Prior radiotherapy allowed * At least 6 weeks since p…